Vanda Pharmaceuticals (VNDA +16.3%) is up on below-average volume in early trade following its announcement of successful results from a 141-subject Phase 2 clinical trial evaluating tradipitant in patients with idiopathic (cause unknown) and diabetic gastroparesis.
The study met the primary endpoint of change in nausea score versus placebo (-1.2 vs. -0.7; p=0.0099). Patients in the treatment group also experienced a statistically significant improvement in the proportion of nausea-free days compared to control (28.8% vs. 15.0%; p=0.0160).
On the safety front, tolerability was similar between tradipitant and placebo.
The company plans to meet with regulatory authorities to clarify a path to registration.
Vanda in-licensed the neurokinin 1 antagonist from Eli Lilly in 2012.
Previously: Vanda's tradipitant shows mixed results in mid-stage dermatitis study (Sept. 13, 2017)
Subscribe for full text news in your inbox